According to a study published on The Lancet, traditional prostate biopsy techniques have 48% accuracy at detecting clinically significant cancer, whereas MRI guided biopsy proved an accuracy of up to 93%, and according to a study performed in Australia, without the use of MRI guided biopsy nearly one in five patients with prostate cancer would have undergone incorrect management of their disease. But Dr. Daniel Cornfeld, Mātai Clinical Lead & Head of Radiology at Te Whatu Ora Tairāwhiti (Gisborne Hospital), is leading a study, in collaboration with Dr. Michael Rice, Urologist at Auckland City Hospital, that focuses on the implementation of this procedure in Tairawhiti Gisborne with the goal of increasing the accuracy of the prostate cancer diagnosis pathway and advocating for guided biopsy as a national standard of care, to improve outcomes and equity in prostate cancer screening and diagnosis.

#gehealthcare

Sources:
The Lancet 2017 study: [ Ссылка ]32401-1/fulltext
Australian study: [ Ссылка ]

Subscribe to GE HealthCare: [ Ссылка ]

Learn more about GE HealthCare
Website: [ Ссылка ]
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]

About GE HealthCare:
As a leading global medical technology and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform.
With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
We embrace a culture of respect, transparency, integrity and diversity.

On Target: Pinpointing Prostate Cancer | Using MRI to guide the biopsy | GE HealthCare
[ Ссылка ]

свернуть